These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31394288)

  • 1. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis.
    Naganuma M; Kobayashi T; Nasuno M; Motoya S; Kato S; Matsuoka K; Hokari R; Watanabe C; Sakamoto H; Yamamoto H; Sasaki M; Watanabe K; Iijima H; Endo Y; Ichikawa H; Ozeki K; Tanida S; Ueno N; Fujiya M; Sako M; Takeuchi K; Sugimoto S; Abe T; Hibi T; Suzuki Y; Kanai T
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1102-1111.e5. PubMed ID: 31394288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
    Kim ES; Lee HS; Kim SK; Kim EY; Jang BI; Kim KO; Yang CH; Lee YJ;
    Scand J Gastroenterol; 2020 Feb; 55(2):163-168. PubMed ID: 31984815
    [No Abstract]   [Full Text] [Related]  

  • 3. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
    Shimizu H; Ebana R; Kudo T; Sato T; Hara T; Hosoi K; Usami M; Yoshida M; Takeuchi I; Nakase H; Iwama I; Arai K; Shimizu T
    J Gastroenterol; 2022 May; 57(5):344-356. PubMed ID: 35165800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
    Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of disease activity by fecal immunochemical test in ulcerative colitis.
    Ryu DG; Kim HW; Park SB; Kang DH; Choi CW; Kim SJ; Nam HS
    World J Gastroenterol; 2016 Dec; 22(48):10617-10624. PubMed ID: 28082814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker.
    Ishida N; Miyazu T; Matsuura T; Takano R; Tamura S; Kagami T; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Sugimoto K
    Int J Colorectal Dis; 2020 Sep; 35(9):1729-1739. PubMed ID: 32472230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.
    Takashima S; Kato J; Hiraoka S; Nakarai A; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H; Tanaka T; Yamamoto K
    Am J Gastroenterol; 2015 Jun; 110(6):873-80. PubMed ID: 25823769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis.
    Sakuraba A; Nemoto N; Hibi N; Ozaki R; Tokunaga S; Kikuchi O; Minowa S; Mitsui T; Miura M; Saito D; Hayashida M; Miyoshi J; Matsuura M; Yoneyama M; Ohnishi H; Hisamatsu T
    BMC Gastroenterol; 2021 May; 21(1):197. PubMed ID: 33933033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fecal calprotectin levels and endoscopic scores for predicting relapse in patients with ulcerative colitis in remission.
    Ishida N; Ito T; Takahashi K; Asai Y; Miyazu T; Higuchi T; Tamura S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K
    World J Gastroenterol; 2023 Dec; 29(47):6111-6121. PubMed ID: 38186681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity.
    Nakov RV; Nakov VN; Gerova VA; Tankova LT
    Folia Med (Plovdiv); 2019 Jun; 61(2):188-196. PubMed ID: 31301663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis.
    Ryu DG; Kim HW; Park SB; Kang DH; Choi CW; Kim SJ; Nam HS
    Medicine (Baltimore); 2019 Sep; 98(36):e17080. PubMed ID: 31490411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
    Dulai PS; Feagan BG; Sands BE; Chen J; Lasch K; Lirio RA
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):456-466.e7. PubMed ID: 35934286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.
    Ishida N; Higuchi T; Miyazu T; Tamura S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Furuta T; Sugimoto K
    Sci Rep; 2021 Jun; 11(1):12431. PubMed ID: 34127687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.
    Nakarai A; Kato J; Hiraoka S; Takashima S; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H
    World J Gastroenterol; 2016 Jun; 22(21):5079-87. PubMed ID: 27275100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study.
    Golovics PA; Gonczi L; Reinglas J; Verdon C; Pundir S; Afif W; Wild G; Bitton A; Bessissow T; Lakatos PL
    Dig Dis Sci; 2022 Jul; 67(7):3089-3095. PubMed ID: 34286411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.